Peptides are short chains of amino acids that serve as building blocks of proteins. In research settings, peptides are studied for their roles in tissue healing, metabolic regulation, and cellular signaling.

Are your products for human consumption?

No. All BLL Peptides products are strictly for in-vitro research and laboratory use only. They are not intended for human or animal consumption.

What is a Certificate of Analysis (COA)?

A COA verifies purity and identity. Every BLL Peptides batch includes HPLC and mass spectrometry results confirming 98%+ purity.

Where are BLL Peptides products manufactured?

All products are 100% USA-manufactured in GMP-certified facilities with independent third-party testing on every batch.

Do you offer free shipping?

Yes — free shipping on all orders over $150 within the continental United States. Orders ship Monday through Friday.

How should peptides be stored?

Lyophilized peptides should be stored at -20°C for long-term stability. Once reconstituted, store at 4°C and use within a few weeks.

Ipamorelin vs GHRP-6: Two Growth Hormone Secretagogues Compared

March 14, 2026

·

Dr. James Nguyen

Introduction

The growth hormone secretagogue class is not uniform, and the differences between compounds in it carry real experimental significance. Ipamorelin is a third-generation GH secretagogue designed specifically to eliminate the cortisol and prolactin elevation seen with earlier compounds like GHRP-6 — it achieves this through receptor subtype selectivity that was mapped out in the mid-1990s by Novo Nordisk’s research group. GHRP-6, by contrast, acts on GHSR-1a with less discrimination, producing a GH pulse alongside measurable increases in cortisol and ghrelin-mediated appetite stimulation. For researchers designing experiments that isolate GH axis effects, that selectivity difference is not a minor footnote — it determines which confounding variables enter the data. This review works through both compounds with that methodological context in view.

Feature	Ipamorelin	GHRP-6
Class	Pentapeptide GHS	Hexapeptide GHS
GHS-R1a Selectivity	Highly selective	Less selective (ACTH, cortisol effects)
GH Pulse Characteristics	Clean, selective GH pulse	Strong GH pulse, broader hormonal response
Cortisol/ACTH Effect	Minimal to none in research	Notable elevation observed
Appetite Stimulation	Minimal in research models	Significant (ghrelin-like effects)
Combination Research	Widely studied with CJC-1295	Studied with GHRH peptides

Ipamorelin Overview

Ipamorelin is a synthetic pentapeptide and selective agonist of the growth hormone secretagogue receptor (GHS-R1a). Developed in the late 1990s, it was designed to provide clean GH stimulation with minimal effects on other pituitary hormones. Research has consistently highlighted Ipamorelin’s exceptional selectivity: unlike earlier GHSs, it does not significantly elevate ACTH, cortisol, prolactin, or LH at GH-stimulating doses in animal models.

The GH pulse produced by Ipamorelin is characterized by a sharp, discrete peak that closely resembles physiological pulsatile secretion. This makes Ipamorelin particularly useful in research designs where isolated somatotropic axis stimulation is desired without confounding neuroendocrine effects. It has been studied extensively in combination with CJC-1295 (no DAC), where their synergistic effects on GH amplitude have been well-documented.

GHRP-6 Overview

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that was among the first GHSs developed and remains one of the most studied. Like Ipamorelin, it binds to GHS-R1a, but with less selectivity — studies have documented concurrent elevations in ACTH and cortisol following GHRP-6 administration, as well as significant appetite stimulation due to its structural similarity to ghrelin.

Despite its broader hormonal footprint, GHRP-6 produces robust GH pulses in research models and has been studied across a wide range of applications including body composition, wound healing, and cardioprotection. Its effects on appetite and GI motility are attributable to ghrelin receptor stimulation in the hypothalamus and enteric nervous system — pathways that have themselves become subjects of independent research interest.

Head-to-Head Comparison

The selectivity gap between Ipamorelin and GHRP-6 is the most clinically and scientifically significant distinction between the two compounds. Ipamorelin’s inability to significantly stimulate cortisol or ACTH release makes it the preferred GHS in research models where stress hormone confounders must be minimized. GHRP-6’s broader activation profile, while potentially limiting in some designs, may be advantageous in research specifically targeting appetite regulation, gut motility, or multi-hormonal interactions.

From a GH pulse standpoint, both peptides produce measurable, dose-dependent GH responses. GHRP-6 may produce somewhat larger pulses in some model systems, but the cleaner hormonal profile of Ipamorelin typically makes it the preferred GHS in contemporary research protocols where data interpretation clarity is paramount.

Research Findings

A landmark study by Raun et al. (1998) established Ipamorelin’s selectivity profile, demonstrating that unlike GHRP-6 and GHRP-2, it did not significantly elevate cortisol, ACTH, or prolactin at doses producing robust GH secretion. This finding positioned Ipamorelin as a benchmark for GHS selectivity research.

GHRP-6 research has produced interesting findings outside the traditional somatotropic axis. Studies in cardiac ischemia models have suggested potential cytoprotective properties, and its effects on GI function have been explored in motility disorder models. The appetite-stimulating properties of GHRP-6 have also made it a useful research tool in cachexia and metabolic wasting models.

Importantly, GHRP-6 is not currently available in the BLL Peptides research catalog. Researchers interested in the GHS-R1a agonist class currently have access to Ipamorelin as the primary compound in this category.

Research-Grade Ipamorelin at BLL Peptides

For researchers studying growth hormone secretagogues, BLL Peptides offers research-grade Ipamorelin:

— High-purity, selective GHS research peptide

Note: GHRP-6 is not currently available in our research catalog. Please check back for catalog updates.

Conclusion

Ipamorelin and GHRP-6 represent two generations of GHS peptide research, with Ipamorelin’s superior selectivity profile making it the preferred compound in most contemporary research designs requiring isolated somatotropic stimulation. GHRP-6’s broader pharmacological footprint, while a liability in some contexts, provides unique research value in appetite, GI, and cardioprotection models. Researchers should select compounds based on specific study objectives and the known receptor selectivity profiles of each peptide.